Pharmacologic and biochemical profiles of new venous antithrombotic beta-D-xyloside derivatives: potential antiathero/thrombotic drugs.
Following a screening program for orally active antithrombotic drugs, it was found that a series of thioxyloside compounds presented with good venous antithrombotic properties. Of more than 500 compounds, LF 09-0055, LF 04-0212, and LF 05-0030 were the most active at inhibiting venous thrombus formation in the rat and rabbit Wessler model after intravenous and oral dosing. LF 05-0030 showed the greatest activity with an ED80 value of 6 mg/kg on oral administration in rats. This activity was maintained in several different models of venous thrombosis and shown to be devoid of anticoagulant effects or hemorrhage. Kinetic studies have demonstrated that maximal levels of activity, following either intravenous or oral dosing, occurred between 2 and 4 hours after administration. This may reflect the type of mechanism involved, since it has been well documented in the literature that xylosides are capable of initiating glycosaminoglycan (GAG) synthesis. Moreover, in vitro galactosyltransferase 1 (the second enzyme involved in GAG polymerization) enzymic assays showed that these thioxyloside derivatives were good acceptors for galactose transfer and therefore at initiating GAG formation. Further in vivo experimentation demonstrated that after treatment by these molecules an important elevation in circulating GAG occurred, with LF 05-0030 presenting the greatest activity, being five times higher than control levels. In addition it was found that dermatan sulfate levels, expressed as antithrombin activity by heparin cofactor II, were significantly increased over control values. As such, this dermatan sulfate moiety is believed to support the antithrombotic activity observed. Studies are underway to investigate the activity of these interesting molecules in atherosclerosis and other vessel wall diseases.
Martin
N B
NB
Centre de Recherche, Laboratoires Fournier, Dijon, France.
Masson
P
P
Sepulchre
C
C
Theveniaux
J
J
Millet
J
J
Bellamy
F
F
D000284:Administration, Oral; D000818:Animals; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000302:isolation & purification / Q000378:metabolism; D005700:Galactosyltransferases / Q000378:metabolism; D006027:Glycosides / Q000008:administration & dosage* / Q000378:metabolism; D007275:Injections, Intravenous; D011817:Rabbits; D051381:Rats; D013927:Thrombosis / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D006027:Glycosides; C010807:xylosides; D005700:Galactosyltransferases